Literature DB >> 19124152

Bone healing induced by local delivery of an engineered parathyroid hormone prodrug.

Isabelle Arrighi1, Silke Mark, Monica Alvisi, Brigitte von Rechenberg, Jeffrey A Hubbell, Jason C Schense.   

Abstract

Regenerative medicine requires innovative therapeutic designs to accommodate high morphogen concentrations in local depots, provide their sustained presence, and enhance cellular invasion and directed differentiation. Here we present an example for inducing local bone regeneration with a matrix-bound engineered active fragment of human parathyroid hormone (PTH(1-34)), linked to a transglutaminase substrate for binding to fibrin as a delivery and cell-invasion matrix with an intervening plasmin-sensitive link (TGplPTH(1-34)). The precursor form displays very little activity and signaling to osteoblasts, whereas the plasmin cleavage product, as it would be induced under the enzymatic influence of cells remodeling the matrix, was highly active. In vivo animal bone-defect experiments showed dose-dependent bone formation using the PTH-fibrin matrix, with evidence of both osteoconductive and osteoinductive bone-healing mechanisms. Results showed that this PTH-derivatized matrix may have potential utility in humans as a replacement for bone grafts or to repair bone defects.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19124152     DOI: 10.1016/j.biomaterials.2008.12.023

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  20 in total

Review 1.  Strategies for controlled delivery of growth factors and cells for bone regeneration.

Authors:  Tiffany N Vo; F Kurtis Kasper; Antonios G Mikos
Journal:  Adv Drug Deliv Rev       Date:  2012-02-04       Impact factor: 15.470

Review 2.  Cellular functions of tissue transglutaminase.

Authors:  Maria V Nurminskaya; Alexey M Belkin
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

3.  Transglutaminase-mediated oligomerization promotes osteoblast adhesive properties of osteopontin and bone sialoprotein.

Authors:  Jennifer Forsprecher; Zhemeng Wang; Harvey A Goldberg; Mari T Kaartinen
Journal:  Cell Adh Migr       Date:  2011-01-01       Impact factor: 3.405

Review 4.  Endogenous tissue engineering: PTH therapy for skeletal repair.

Authors:  Masahiko Takahata; Hani A Awad; Regis J O'Keefe; Susan V Bukata; Edward M Schwarz
Journal:  Cell Tissue Res       Date:  2011-05-31       Impact factor: 5.249

5.  Biomimetic CaP coating incorporated with parathyroid hormone improves the osseointegration of titanium implant.

Authors:  Xiaohua Yu; Liping Wang; Xi Jiang; David Rowe; Mei Wei
Journal:  J Mater Sci Mater Med       Date:  2012-05-26       Impact factor: 3.896

Review 6.  Recommendations and considerations for the use of biologics in orthopedic surgery.

Authors:  Stefan Zwingenberger; Christophe Nich; Roberto D Valladares; Zhenyu Yao; Maik Stiehler; Stuart B Goodman
Journal:  BioDrugs       Date:  2012-08-01       Impact factor: 5.807

Review 7.  Fibrin glue as a drug delivery system.

Authors:  Patrick P Spicer; Antonios G Mikos
Journal:  J Control Release       Date:  2010-07-15       Impact factor: 9.776

8.  BMP2 cross-linked by transglutaminase 2 to collagen-plla scaffold promotes osteogenic differentiation in mesenchymal stem cells.

Authors:  Kelly E Beazley; Maria Nurminskaya
Journal:  Biotechnol Lett       Date:  2014-06-15       Impact factor: 2.461

9.  Induction of chondrogenic differentiation in mesenchymal stem cells by TGF-beta cross-linked to collagen-PLLA [poly(L-lactic acid)] scaffold by transglutaminase 2.

Authors:  Corinne Niger; Kelly E Beazley; Maria Nurminskaya
Journal:  Biotechnol Lett       Date:  2013-07-27       Impact factor: 2.461

10.  Engineering fibrin matrices: the engagement of polymerization pockets through fibrin knob technology for the delivery and retention of therapeutic proteins.

Authors:  Allyson S C Soon; Sarah E Stabenfeldt; Wendy E Brown; Thomas H Barker
Journal:  Biomaterials       Date:  2009-11-14       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.